Get started
Karuna Therapeutics, Inc.Karuna Therapeutics, Inc.Karuna Therapeutics, Inc.

Karuna Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

KRTX chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
—
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−11.7263USD
Net income (FY)
‪−433.68 M‬USD
Revenue (FY)
‪654.00 K‬USD
Shares float
—
Beta (1Y)
1.73

About Karuna Therapeutics, Inc.

Sector
Health Technology
Headquarters
Boston
Employees (FY)
339
Website
karunatx.com
Founded
2009
Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of KRTX is 329.8300 USD — it has increased by 0.03% in the past 24 hours. Watch Karuna Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Karuna Therapeutics, Inc. stocks are traded under the ticker KRTX.
We've gathered analysts' opinions on Karuna Therapeutics, Inc. future price: according to them, KRTX price has a max estimate of 330.00 USD and a min estimate of 330.00 USD. Watch KRTX chart and read a more detailed Karuna Therapeutics, Inc. stock forecast: see what analysts think of Karuna Therapeutics, Inc. and suggest that you do with its stocks.
KRTX stock is 0.08% volatile and has beta coefficient of 1.73. Track Karuna Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Karuna Therapeutics, Inc. there?
Yes, you can track Karuna Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Karuna Therapeutics, Inc. is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
KRTX earnings for the last quarter are −2.67 USD per share, whereas the estimation was −2.67 USD resulting in a 0% surprise. The estimated earnings for the next quarter are −3.15 USD per share. See more details about Karuna Therapeutics, Inc. earnings.
Karuna Therapeutics, Inc. revenue for the last quarter amounts to ‪13.25 M‬ USD despite the estimated figure of ‪13.25 M‬ USD. In the next quarter revenue is expected to reach ‪2.25 M‬ USD.
KRTX net income for the last quarter is ‪−113.82 M‬ USD, while the quarter before that showed ‪−119.12 M‬ USD of net income which accounts for 4.45% change. Track more Karuna Therapeutics, Inc. financial stats to get the full picture.
No, KRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 1, 2024, the company has 339.00 employees. See our rating of the largest employees — is Karuna Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Karuna Therapeutics, Inc. EBITDA is ‪−493.08 M‬ USD, and current EBITDA margin is ‪−75.39 K‬%. See more stats in Karuna Therapeutics, Inc. financial statements.
Like other stocks, KRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Karuna Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Karuna Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Karuna Therapeutics, Inc. stock shows the buy signal. See more of Karuna Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.